Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
26 studies found for:    mt103
Show Display Options
Rank Status Study
1 Completed
Has Results
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: Blinatumomab (MT103)
2 Completed
Has Results
Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL
Condition: Non-Hodgkin's Lymphoma, Relapsed
Intervention: Biological: Blinatumomab (MT103)
3 Active, not recruiting
Has Results
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
Condition: B-ALL
Intervention: Biological: Blinatumomab
4 Active, not recruiting
Has Results
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: B-cell Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab
5 Recruiting Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Procedure: hematopoietic cell transplantation
6 Active, not recruiting
Has Results
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: Blinatumomab
7 Active, not recruiting
Has Results
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Condition: Diffuse Large B-cell Lymphoma
Intervention: Drug: Blinatumomab
8 Recruiting Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
Conditions: B Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: Blinatumomab;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Prednisone;   Drug: Vincristine Sulfate
9 Completed Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: blinatumomab
10 Active, not recruiting Phase 2 Trial of Blinatumomab in Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia
Condition: Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab
11 Recruiting Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Condition: B Acute Lymphoblastic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
12 Not yet recruiting Hyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Conditions: Leukemia;   Acute Lymphoblastic Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: MESNA;   Drug: Dexamethasone;   Drug: Ofatumumab;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cytarabine;   Drug: Rituximab;   Drug: Pegfilgrastim;   Drug: G-CSF;   Drug: Leucovorin;   Drug: Blinatumomab;   Drug: 6-Mercaptopurine;   Drug: Prednisone;   Behavioral: Phone Calls
13 Not yet recruiting Study to Evaluate Safety and Efficacy of Blinatuomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
Condition: B-Cell Non Hodgkin Lymphoma
Interventions: Drug: Blinatumomab;   Drug: Investigator's Choice Chemotherapy
14 Active, not recruiting Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Condition: Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Drug: Standard of Care Chemotherapy
15 Recruiting Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Mediastinal Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma
Interventions: Biological: Blinatumomab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
16 Not yet recruiting Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Conditions: B Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   CD19-Positive Neoplastic Cells Present;   Mixed Phenotype Acute Leukemia;   Mixed Phenotype Acute Leukemia With t(9;22)(q34;q11.2); BCR-ABL1
Interventions: Biological: Blinatumomab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
17 Recruiting Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Condition: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Blinatumomab
18 Not yet recruiting A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Blinatumomab
19 Recruiting Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Vincristine Sulfate
20 Recruiting Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL
Condition: Leukemia, Acute Lymphoblastic
Interventions: Drug: Blinatumomab;   Drug: Conventional Consolidation Chemotherapy

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Indicates status has not been verified in more than two years